Targeting glioblastoma and breast cancer with integrin alpha10-binding ADCs.
| Reference number | |
| Coordinator | Xintela AB |
| Funding from Vinnova | SEK 1 988 643 |
| Project duration | April 2020 - December 2021 |
| Status | Completed |
| Venture | Innovation projects in enterprises |
| Call | Innovation projects in small and medium-sized companies - autumn 2019 |
Important results from the project
Our previous studies have demonstrated the potential of integrin alpha10beta1 as a therapeutic target for the development of antibody-based treatments of aggressive tumors. In this project, we investigated integrin alpha10 as a potential drug target in glioblastoma and breast cancer. This preclinical programme is the first step of our antibody drug conjugate (ADC) development programmes for the treatment of glioblastoma and breast cancer. In this study, we have confirmed Proof of Principle for our ADC candidates in both in vitro and in vivo studies.
Expected long term effects
The project successfully confirmed the proof of principle for integrin alpha10-targeted ADC candidates for the treatment of glioblastoma and breast cancer. This allows us to select the lead candidate for humanization and subsequently enable the company to attract a development partner to take our lead ADC to the market and to the cancer patients.
Approach and implementation
The project was divided into 4 work packages and supposed to be implemented over a course of 21 months. 1. ADC design and identification of candidates that may improve therapeutic strategy. Planned Start: 04. 2020 End: 08.2020 2. Production of identified ADC candidates Start: 08.2020 End: 11.2020 3. Efficacy testing in vitro Start: 12.2020 End: 05.2021 4. Efficacy testing in vivo Start:04. 2020 End:12.2021 All the work packages were finished on time. Besides the four work packages, we could also humanize the lead antibody and conjugated the new ADC for in vitro and in vivo efficacy test.